Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytrx Cp (CYTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 91,230
  • Shares Outstanding, K 152,050
  • Annual Sales, $ 200 K
  • Annual Income, $ -50,770 K
  • 36-Month Beta 2.32
  • Price/Sales 475.17
  • Price/Cash Flow 0.00
  • Price/Book 5.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/04/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.25 on 03/07/08
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.50 +20.00%
on 07/12/17
0.76 -21.05%
on 06/23/17
-0.07 (-10.45%)
since 06/21/17
3-Month
0.41 +46.34%
on 05/17/17
0.99 -39.39%
on 04/24/17
-0.01 (-1.64%)
since 04/21/17
52-Week
0.36 +66.67%
on 12/28/16
0.99 -39.39%
on 04/24/17
unch (unch)
since 07/21/16

Most Recent Stories

More News
Breakfast Technical Briefing on Biotech Stocks -- CytRx, Keryx Biopharma, TG Therapeutics, and ZIOPHARM Oncology

If you want a Stock Review on CYTR, KERX, TGTX or ZIOP then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Biotechnology is an industry that focuses...

TGTX : 12.20 (+4.27%)
KERX : 7.24 (+2.40%)
ZIOP : 6.10 (unch)
CYTR : 0.60 (-4.00%)
Today's Research Reports on Stocks to Watch: CytRx and Hydrogenics Corporation

NEW YORK, NY / ACCESSWIRE / June 9, 2017 / CytRx's shares saw a big gaining day yesterday after the company announced a big regulatory pathway update about aldoxorubicin, a tumor-targeted doxorubicin...

CYTR : 0.60 (-4.00%)
HYGS : 8.80 (-2.76%)
Today's Research Reports on Stocks to Watch: Endocyte and CytRx

NEW YORK, NY / ACCESSWIRE / May 31, 2017 / While still not anywhere the highs of 2015's boom, the Biotech Industry has shown some signs of a comeback in 2017. After a dismal 2016, the iShares NASDAQ Biotechnology...

ECYT : 1.43 (+0.70%)
CYTR : 0.60 (-4.00%)
XBI : 80.77 (+0.79%)
CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of two abstracts at the 2017 American Society of Clinical...

CYTR : 0.60 (-4.00%)
CytRx Reports First Quarter 2017 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ended March 31, 2017, and provided an...

CYTR : 0.60 (-4.00%)
CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a public offering of approximately 30 million shares...

CYTR : 0.60 (-4.00%)
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up

CytRx Corporation (CYTR) announced that the it has reached an agreement with the regarding the path to filing for its new drug application (NDA) for its lead candidate aldoxorubicin being developed for...

HSKA : 100.17 (-1.22%)
GALE : 0.58 (unch)
LLY : 84.66 (-0.11%)
CYTR : 0.60 (-4.00%)
Blog Coverage CytRx Announces FDA's Approval for New Drug Application

Upcoming AWS Coverage on Alexion Pharmaceuticals Post-Earnings Results

CYTR : 0.60 (-4.00%)
ALXN : 131.79 (+1.53%)
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR) today announced the U.S. Food and Drug Administration (FDA) has reached an agreement with CytRx on preparations for a New Drug Application (NDA) submission for aldoxorubicin...

CYTR : 0.60 (-4.00%)
CytRx Reports 2016 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the year ended December 31, 2016, and provided an...

CYTR : 0.60 (-4.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

See More

Support & Resistance

2nd Resistance Point 0.65
1st Resistance Point 0.62
Last Price 0.60
1st Support Level 0.58
2nd Support Level 0.57

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.